In silico insights on Disialoganglioside GD2 : A Potential target for Pediatric Neuroblastoma.
The In silico approach provides a platform for determination and establishing a potential inhibitor against GD2 in Pediatric neuroblastoma. Originating from the abnormal growth of neuroblasts, pediatric neuroblastoma affects the age group below 15 years. It is an aggressive heterogenous cancer with a high morbidity rate. Biological marker GD2 synthesised by the GD2 gene, acts as a powerful predictor of neuroblastoma cells. The In silico approach provides a platform for determination and establishing a potential inhibitor against GD2 in Pediatric neuroblastoma. A total of 18 established drugs were subjected to molecular docking .Through high throughput studies the best similar drug to the established drug Etoposide (CID: 36462) with most affinity was established. The experiment resulted in compound having PubChem ID 10254934 showing better affinity than the established drug against GD2. The comparative profiling of the two compounds on the basis various interactions such H bond interaction, aromatic interactions, electrostatic interactions along with ADMET profiling and toxicity studies was carried out using different suites and softwares Result: The docking separated the virtual screened drug (PubChemID: 10254934) from established drug with a better rerank score of -136.33. The toxicity profile of the virtual screened drug is also lesser (less lethal) than the established drug. The virtual screened drug bioavailable as it does not crosses the blood brain barrier. Conclusively, the virtual screened drug is better inhibitor than the established drug and can be further subjected for wet lab studies.